Backer MV - Search Results

1

Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.

Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV, Backer JM. Rusckowski M, et al. Among authors: backer mv. EJNMMI Res. 2016 Dec;6(1):4. doi: 10.1186/s13550-016-0163-1. Epub 2016 Jan 16. EJNMMI Res. 2016. PMID: 26780081 Free PMC article.

2

Overexpression of NM23-1 enhances responsiveness of IMR-32 human neuroblastoma cells to differentiation stimuli.

Backer MV, Kamel N, Sandoval C, Jayabose S, Mendola CE, Backer JM. Backer MV, et al. Among authors: backer jm. Anticancer Res. 2000 May-Jun;20(3A):1743-9. Anticancer Res. 2000. PMID: 10928103

3

Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling.

Tao Q, Backer MV, Backer JM, Terman BI. Tao Q, et al. Among authors: backer mv, backer jm. J Biol Chem. 2001 Jun 15;276(24):21916-23. doi: 10.1074/jbc.M100763200. Epub 2001 Mar 16. J Biol Chem. 2001. PMID: 11399777 Free article.

4

Molecular vehicle for target-mediated delivery of therapeutics and diagnostics.

Gaidamakova EK, Backer MV, Backer JM. Gaidamakova EK, et al. Among authors: backer mv, backer jm. J Control Release. 2001 Jul 6;74(1-3):341-7. doi: 10.1016/s0168-3659(01)00345-5. J Control Release. 2001. PMID: 11489516

5

Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2.

Backer MV, Budker VG, Backer JM. Backer MV, et al. Among authors: backer jm. J Control Release. 2001 Jul 6;74(1-3):349-55. doi: 10.1016/s0168-3659(01)00346-7. J Control Release. 2001. PMID: 11489517

6

Functionally active VEGF fusion proteins.

Backer MV, Backer JM. Backer MV, et al. Among authors: backer jm. Protein Expr Purif. 2001 Oct;23(1):1-7. doi: 10.1006/prep.2001.1472. Protein Expr Purif. 2001. PMID: 11570839

7

Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins.

Backer MV, Backer JM. Backer MV, et al. Among authors: backer jm. Bioconjug Chem. 2001 Nov-Dec;12(6):1066-73. doi: 10.1021/bc015534j. Bioconjug Chem. 2001. PMID: 11716701

8

Molecular vehicles for targeted drug delivery.

Backer MV, Aloise R, Przekop K, Stoletov K, Backer JM. Backer MV, et al. Among authors: backer jm. Bioconjug Chem. 2002 May-Jun;13(3):462-7. doi: 10.1021/bc0155770. Bioconjug Chem. 2002. PMID: 12009934

9

Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery.

Backer MV, Gaynutdinov TI, Aloise R, Przekop K, Backer JM. Backer MV, et al. Among authors: backer jm. Protein Expr Purif. 2002 Dec;26(3):455-61. doi: 10.1016/s1046-5928(02)00546-6. Protein Expr Purif. 2002. PMID: 12460770

10

Humanized docking system for assembly of targeting drug delivery complexes.

Backer MV, Gaynutdinov TI, Gorshkova II, Crouch RJ, Hu T, Aloise R, Arab M, Przekop K, Backer JM. Backer MV, et al. Among authors: backer jm. J Control Release. 2003 May 20;89(3):499-511. doi: 10.1016/s0168-3659(03)00150-0. J Control Release. 2003. PMID: 12737851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters